Alvotech (ALVO) Receives FDA Form 483 Following Routine Facility Inspection
Key takeaways
- On May 11, Alvotech announced the completion of a routine FDA surveillance inspection at its manufacturing facility in Reykjavik, Iceland.
- Management views the results as a validation of the facility’s current cGMP fundamentals and the effectiveness of improvements implemented over the past year.
- Alvotech (NASDAQ:ALVO) maintains its outlook for achieving FDA approval for these BLAs within the 2026 calendar year.
Alvotech (ALVO) Receives FDA Form 483 Following Routine Facility Inspection Maham Fatima Sat, June 6, 2026 at 10:44 PM GMT+7 1 min read ALVO Alvotech (NASDAQ:ALVO) is one of the most promising penny stocks according to Wall Street analysts. On May 11, Alvotech announced the completion of a routine FDA surveillance inspection at its manufacturing facility in Reykjavik, Iceland. While the FDA issued a Form 483 at the conclusion of the visit on May 8, 2026, the company stated that it believes the observations are manageable and do not indicate significant issues with the site’s overall operations or compliance.
Management views the results as a validation of the facility’s current cGMP fundamentals and the effectiveness of improvements implemented over the past year. Consequently, the company remains on schedule to resubmit its relevant BLAs during Q2 2026.
Alvotech (NASDAQ:ALVO) maintains its outlook for achieving FDA approval for these BLAs within the 2026 calendar year. The company continues to focus on finalizing the necessary data compilation to support the upcoming regulatory submissions.